The Center for Biosimilars Staff


Eye on Pharma: Mylan and Biocon Launch Biosimilar Trastuzumab, Ogivri, in Australia

August 03, 2019

Mylan and Biocon announced this week that they have launched their biosimilar trastuzumab, Ogivri, in Australia. Ogivri, referencing Herceptin, is the first trastuzumab biosimilar to launch in the Australian marketplace and is listed on the nation’s Pharmaceutical Benefit Scheme.

HHS Announces Plan to Allow Importation of Foreign Drugs, Potentially Including Insulin

July 31, 2019

The first pathway for importation outlined in the plan would rely on a notice of proposed rulemaking to authorize importation of drugs from Canada. The second pathway would allow manufacturers to import versions of FDA-approved drugs that are sold in other countries.

Alvotech, Cipla Create Partnership to Sell Adalimumab Biosimilar

July 29, 2019

Biopharmaceutical company Alvotech and Cipla Gulf entered into an exclusive partnership for the commercialization of AVT02, an adalimumab biosimilar, in certain emerging markets, the companies reported Monday. Alvotech's AVT02 is in phase 3 trials; the companies expect to file for approval with the European Medicines Agency and the FDA by early next year.

Finnish Study Finds Anti-TNF Agents More Cost-Effective Than Rituximab in RA

July 25, 2019

A patient-level simulation model using real-world data from Finland evaluated the cost-effectiveness of abatacept, tocilizumab, and anti–tumor necrosis factor (anti-TNF) therapies as compared with rituximab in patients with rheumatoid arthritis (RA) who received previous treatment with an anti-TNF agent.

JCR's Proposed Darbepoetin Alfa Biosimilar Performs in Phase 3 Program

July 25, 2019

JCR Pharmaceuticals, together with partner Kissei Pharmaceutical, is currently developing a darbepoetin alfa biosimilar, JR-131, referencing Aranesp. Darbepoetin alfa is used to treat anemia caused by chronic kidney disease or by chemotherapy.

Canadian Payer Applauds British Columbia for Switching Patients to Biosimilars

July 23, 2019

This month, the president and chief executive officer of Green Shield Canada, the fourth-largest private payer in Canada, hailed British Columbia’s strategy as “forward-thinking” and “essential to maximizing opportunities in healthcare.”

Using Value-Based RA Pathway Leads to a Shift to Biosimilars for AHG

July 17, 2019

A variety of policy proposals have been put forward to help spur the US uptake of biosimilars, from legislative solutions to regulatory changes, but some providers are taking the matter into their own hands with concerted efforts to bring biosimilars to the clinic.